Scope
Reference
DACPM2025-26
Description
PROCUREMENT OF ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL.
Contract 1. ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL,
Supplier
Contract value
- £750,000 excluding VAT
- £750,000 including VAT
Above the relevant threshold
Earliest date the contract will be signed
16 June 2025
Contract dates (estimated)
- 17 June 2025 to 30 June 2027
- 2 years, 14 days
Main procurement category
Goods
CPV classifications
- 33600000 - Pharmaceutical products
Contract locations
- UKN - Northern Ireland
Other information
Conflicts assessment prepared/revised
Yes
Procedure
Procedure type
Direct award
Direct award justification
Additional or repeat goods, services or works - extension or partial replacement
These essential medicines are required for continuity of patient care. These medicines are available only from one economic operator. BHSCT can confirm that the absence of competition is not a result of the artificial narrowing of the parameters of the procurement.
Supplier
ALLOGA UK LIMITED
- Companies House: 03169255
- Public Procurement Organisation Number: PBTH-6754-GVPN
Amber Park
Alfreton
DE55 2FH
United Kingdom
Email: allogauk.enquiries@alloga.co.uk
Website: https://www.alloga.co.uk/
Region: UKF12 - East Derbyshire
Small or medium-sized enterprise (SME): No
Voluntary, community or social enterprise (VCSE): No
Contract 1. ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL,
Contracting authority
Belfast Health & Social Care Trust
- Public Procurement Organisation Number: PLQJ-5727-JCLR
Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital
Belfast
BT12 6BA
United Kingdom
Region: UKN06 - Belfast
Organisation type: Public authority - central government
Devolved regulations that apply: Northern Ireland